A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants

作者：Nahimana A; Aubry D; Lagopoulos L; Greaney P; Attinger A; Demotz S; Dawson K M; Schapira M; Tschopp J; Dupuis M; Duchosal M A^*

来源：Blood Cancer Journal, 2011, 1: e47.

DOI：10.1038/bcj.2011.47

• Fas
• bone marrow purging
• hematopoietic stem cell transplantation
• lymphoma
• leukemia

There remains a clear need for effective tumor cell purging in autologous stem cell transplantation (ASCT) where residual malignant cells within the autograft contribute to disease relapse. Here we propose the use of a novel Fas agonist with potent pro-apoptotic activity, termed MegaFasL, as an effective ex-vivo purging agent. MegaFasL selectively kills hematological cancer cells from lymphomas and leukemias and prevents tumor development at concentrations that do not reduce the functional capacity of human hematopoietic stem/progenitor cells both in in vitro and in in vivo transplantation models. These findings highlight the potential use of MegaFasL as an ex-vivo purging agent in ASCT. Blood Cancer Journal (2011) 1, e47; doi: 10.1038/bcj.2011.47; published online 9 December 2011

• 出版日期2011-12